$29

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

3 weeks ago

RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025

September 26, 2025 06:00 ET  | Source: RadNet, Inc. LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:…

3 weeks ago

VivoPower Commences $29 Million Shareholder Loan Financing Retirement Plan

LONDON, July 07, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”) announced today that its…

3 months ago